var data={"title":"Factor IX, recombinant human with albumin fusion: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Factor IX, recombinant human with albumin fusion: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/794833?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=factor-ix-recombinant-human-with-albumin-fusion-patient-drug-information\" class=\"drug drug_patient\">see &quot;Factor IX, recombinant human with albumin fusion: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46305844\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Idelvion</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46360564\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Idelvion</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46245252\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihemophilic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46360597\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Note:</b> Dose and duration of treatment depends on the severity of factor IX deficiency, the location and extent of bleeding, and the patient&rsquo;s clinical condition, age, and recovery of factor IX. Adjust dosing regimen based on individual response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hemophilia B (congenital factor IX deficiency):</b> The calculation of the required dose is based on 1 unit/kg body weight is expected to increase the factor IX circulating level by 1.3 units/dL in adults. The required dose is determined by the following formula: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Number of factor IX units required = patient weight (in kg) x desired factor IX level increase (as % or units/dL) x reciprocal of recovery (as units/kg per units/dL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>On-demand control and prevention of bleeding episodes:</b> IV:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"left\"></col>\n      <col align=\"left\"></col>\n      <col align=\"left\"></col>\n      <col align=\"left\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Type of bleeding episode</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Required circulating factor IX activity</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dosing frequency</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Duration of therapy </p></th></tr></thead>\n      <tbody valign=\"top\">\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <b>Minor or moderate</b> (uncomplicated hemarthrosis, muscle bleeding [except iliopsoas] or oral bleeding)</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">30 to 60 units/dL</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">48 to 72 hours</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">At least 1 day, until bleeding stops and healing is achieved. Single dose should be sufficient for majority of bleeds.  </p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <b>Major</b> (life or limb threatening hemorrhage, deep muscle bleeding, including iliopsoas,  intracranial, retropharyngeal) </p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">60 to 100 units/dL</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">48 to 72 hours </p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">7 to 14 days, or until bleeding stops and healing is achieved. Maintenance dose weekly.  </p></td></tr></tbody></table>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Perioperative management of bleeding:</b> IV: </p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"left\"></col>\n      <col align=\"left\"></col>\n      <col align=\"left\"></col>\n      <col align=\"left\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Type of bleeding surgery</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Required circulating factor IX activity</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dosing frequency</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Duration of therapy </p></th></tr></thead>\n      <tbody valign=\"top\">\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <b>Minor</b> (including uncomplicated  tooth extraction)</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">50 to 80 units/dL </p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">48 to 72 hours</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">At least 1 day, until bleeding stops and healing is achieved. Single dose should be sufficient for majority of minor surgeries.</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <b>Major</b> (including intracranial, pharyngeal, retropharyngeal, retroperitoneal) </p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">60 to 100 units/dL</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">48 to 72 hours </p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">7 to 14 days, or until bleeding stops and healing is achieved. Repeat dose every 48 to 72 hours for the first week or until healing is achieved. Maintenance dose 1 to 2 times per week</p></td></tr></tbody></table>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Routine prophylaxis:</b> IV: 25 to 40 units/kg once every 7 days; if well controlled may switch to 50 to 75 units/kg once every 14 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46361337\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Note:</b> Dose and duration of treatment depends on the severity of factor IX deficiency, the location and extent of bleeding, and the patient&rsquo;s clinical condition, age, and recovery of factor IX. Adjust dosing regimen based on individual response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hemophilia B (congenital factor IX deficiency):</b> The calculation of the required dose is based on 1 unit/kg body weight is expected to increase the factor IX circulating level by 1 units/dL in infants and children &lt;12 years and by 1.3 units/dL in Children &ge;12 years and Adolescents. The required dose is determined by the following formula:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Number of factor IX units required = patient weight (in kg) x desired factor IX level increase (as % or units/dL) x reciprocal of recovery (as units/kg per units/dL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>On-demand control and prevention of bleeding episodes:</b> Infants, Children, and Adolescents: IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Perioperative management of bleeding: </b> Infants, Children, and Adolescents: IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Routine prophylaxis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>US labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;12 years: IV: 40 to 55 units/kg once every 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Canadian labeling:</i> Infants, Children &ge;12 years, and Adolescents: IV: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46360601\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46360602\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturers labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46360603\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturers labeling; use with caution in patients with hepatic disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46305845\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Idelvion: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea) [contains hamster protein, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46305843\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46360605\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV injection only. Do not use if particulate matter or discoloration is observed. Adjust infusion rate to comfort level of the patient, not exceeding 10 mL/minute. Administer at room temperature and within 4 hours of reconstitution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46245254\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemophilia B (congenital factor IX deficiency): </b>  Prevention and on-demand control of bleeding episodes in adults and children; perioperative management of bleeding in adults and children; routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Limitations of use: Not indicated for immune tolerance induction in patients with hemophilia B.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46360563\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Factor IX (Recombinant [albumin fusion protein]) may be confused with other factor IX products</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46364576\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Dizziness, eczema, hypersensitivity reaction, infusion related reaction, nephrotic syndrome, skin rash</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46245255\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Life-threatening hypersensitivity to factor IX (recombinant [albumin fusion protein]) or any component of the formulation including hamster proteins</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46360568\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: Neutralizing antibodies (inhibitors) to factor IX may develop; monitor for development of antibodies with lab tests and clinical observation. Perform assay to measure factor IX inhibitor concentration if expected plasma factor IX activity levels are not attained or if bleeding is not controlled at an appropriate dose. Patients with factor IX inhibitors are at increased risk for severe hypersensitivity reactions or anaphylaxis upon re-exposure. Evaluate patients experiencing allergic reactions for the presence of an inhibitor. Monitor patients with inhibitors for signs/symptoms of acute hypersensitivity, particularly in the early phases of exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions (including anaphylaxis) may occur; early signs include angioedema, chest tightness, hypotension, urticarial (generalized) wheezing, and dyspnea. Discontinue immediately (and manage appropriately) if symptoms of hypersensitivity occur. Contains trace amounts of Chinese hamster ovary proteins; hypersensitivity to these proteins may develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotic syndrome: Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patient with factor IX inhibitors and a history of allergic reactions. Safety and efficacy in this situation have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: Thromboembolism (eg, pulmonary embolism, venous/arterial thrombosis) may occur. Monitor for early signs of thromboembolism and coagulopathy in patients with hepatic disease, fibrinolysis, perioperative status, or risk factors for thromboembolic events or disseminated intravascular coagulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46283953\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46283950\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=107193&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46360566\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Animal reproduction studies have not been conducted. Information specific to the use of this product in pregnancy has not been located.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Factor IX concentrations do not change significantly in pregnant women with coagulation disorders, and women with factor IX deficiency may be at increased risk of postpartum hemorrhage. Pregnant women should have clotting factors monitored, particularly at 28 and 34 weeks gestation and prior to invasive procedures. Prophylaxis may be needed if factor IX concentrations are &lt;50 units/mL at term, and treatment should continue for 3 to 5 days postpartum depending on route of delivery. The neonate may also be at an increased risk of bleeding following delivery and should be tested for the coagulation disorder (Kadir 2009; Lee 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46360567\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if factor IX (recombinant) is excreted in breast milk. According to the manufacturer, the decision to breast-feed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46360607\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor factor IX levels by the one-stage clotting assay to confirm adequate factor IX levels are achieved/maintained (measure 15 minutes after infusion to verify calculated doses (WFH [Srivastava 2013]), aPTT, BP, HR, signs of hypersensitivity reactions, DIC, and thrombosis; screen for factor IX inhibitors if the patient experiences hypersensitivity reaction or when patient is to undergo surgery, if suboptimal response to treatment occurs, if patient is being intensively treated for &gt;5 days within 4 weeks of the last infusion, or at the following intervals (WFH [Srivastava 2013]):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Children: Screen for inhibitors every 5 exposure days until 20 exposure days, every 10 exposure days between 21 to 50 exposure days, and at a minimum of twice a year until 150 exposure days is reached.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults (with &gt;150 exposure days apart from a 6 to 12 monthly review): Screen for inhibitors when suboptimal response occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46360572\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Factor IX (recombinant [albumin fusion protein]) is a recombinant protein that temporarily replaces the missing coagulation factor IX needed for effective hemostasis in patients with hemophilia B. Factor IX (recombinant [albumin fusion protein]) is comprised of genetically fused recombinant coagulation factor IX and recombinant albumin. Fusion with recombinant albumin extends the half-life of factor IX.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46360574\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Adults: V<sub>ss</sub>: 0.86 to 1.2 dL/kg; Children and Adolescents &lt;18 years: 1.16 to 1.42 dL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Adults: 104 to 118 hours; Infants, Children, and Adolescents &lt;18 years: 87 to 93 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46312631\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Idelvion Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $5.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $5.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $5.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $5.28</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50663218\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Idelvion (AT, AU, CZ, DE, DK, EE, ES, FR, GB, HR, HU, LT, LU, LV, NO, PL, PT, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-with-albumin-fusion-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-with-albumin-fusion-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Idelvion (factor IX [recombinant (albumin fusion protein)]) [prescribing information]. Kankakee, IL: CSL Behring LLC; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-with-albumin-fusion-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleeding disorders. <i>Haemophilia</i>. 2009;15(5):990-1005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-with-albumin-fusion-drug-information/abstract-text/19298378/pubmed\" target=\"_blank\" id=\"19298378\">19298378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee CA, Chi C, Pavord SR, et al. The obstetric and gynaecological management of women with inherited bleeding disorders--review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization. <i>Haemophilia</i>. 2006;12(4):301-336.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-with-albumin-fusion-drug-information/abstract-text/16834731/pubmed\" target=\"_blank\" id=\"16834731\">16834731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-with-albumin-fusion-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-with-albumin-fusion-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on Behalf of The World Federation of Hemophilia. Guidelines for the management of hemophilia. <i>Haemophilia</i>. 2013;19(1):e1-e47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-with-albumin-fusion-drug-information/abstract-text/22776238/pubmed\" target=\"_blank\" id=\"22776238\">22776238</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 107193 Version 20.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F46305844\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F46360564\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F46245252\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F46360597\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F46361337\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F46360601\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F46360602\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F46360603\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F46305845\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F46305843\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F46360605\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F46245254\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F46360563\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F46364576\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F46245255\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F46360568\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F46283953\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F46283950\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F46360566\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F46360567\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F46360607\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F46360572\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F46360574\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F46312631\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F50663218\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/107193|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=factor-ix-recombinant-human-with-albumin-fusion-patient-drug-information\" class=\"drug drug_patient\">Factor IX, recombinant human with albumin fusion: Patient drug information</a></li></ul></div></div>","javascript":null}